RGNX (Regenxbio) Tariff Resilience Score: 6/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RGNX Regenxbio Inc RGNX
59 GF Score
Price $9.89
GF Value $14.96
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Regenxbio Tariff Resilience Score?

Regenxbio RGNX -11.70% 59 Tariff Resilience Score is 6 as of Jul. 18, 2026. GuruFocus rates RGNX with a GF Score™ of 59/100 and a GF Value™ of $14.96 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,370 Biotechnology companies, Regenxbio ranks better than 75.99% on this metric.

Regenxbio has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Regenxbio has Regenxbio, a biotech firm, is moderately exposed to tariffs due to global supply chain dependencies for research materials. However, its innovative products and potential pricing power offer some mitigation.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Regenxbio might have Average Resilient.

Regenxbio  (NAS:RGNX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Regenxbio Tariff Resilience Score Related Terms

RGNX vs ALT, ASMB, CTNM: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Regenxbio's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenxbio Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Regenxbio's Tariff Resilience Score falls into.


RGNX
59GF Score
Regenxbio Inc RGNX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Regenxbio (RGNX) has a Tariff Resilience Score of 6 as of Jul. 18, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Regenxbio ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is Regenxbio's Tariff Resilience Score too high?
Regenxbio's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Regenxbio's value of 6 is 50% above this industry median. Based on the distribution chart, Regenxbio ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Regenxbio has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Regenxbio's Tariff Resilience Score compare to ALT and ASMB?
According to the Biotechnology industry distribution chart, Regenxbio ranks #329 out of 1370 companies for Tariff Resilience Score. This places Regenxbio in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Regenxbio's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regenxbio's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenxbio's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenxbio stock overvalued right now?
Based on GuruFocus' analysis, Regenxbio (RGNX) is currently considered Possible Value Trap. The stock's GF Value™ is $14.96, compared to a current price of $9.89 — trading 33.9% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Regenxbio's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Regenxbio (RGNX), the current Tariff Resilience Score is 6 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regenxbio (RGNX) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be undervalued. The current stock price of $9.89 is trading 33.9% below its estimated GF Value™ of $14.96. GuruFocus considers Regenxbio to be Possible Value Trap.

Key valuation signals for RGNX:

  • Tariff Resilience Score: 6
  • GF Value™: $14.96 vs. price of $9.89 (33.9% below fair value)
  • GF Score™: 59/100 with 6 warning signs
  • Industry Position: 50% above the Biotechnology median (#329 of 1370)

No single metric tells the full story. See the RGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regenxbio Business Description

Other Exchanges RB0:Germany
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
59GF Score

Get the complete analysis for RGNX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.89
Price
$14.96
GF Value